Late last year, GSK said it would release (anonymous) patient level information from clinical trials to allow researchers more access to provide independent analytics. It is sticking to its guns by endorsing the AllTrials movement to do just that. GSK also says that it is working on its web porthole that will provide researchers the promised open -- yet secure -- access to trial data.
PhRMA -- which GSK belongs to -- and the Association for British Pharmaceutical Industry however both demur, saying it is a bad idea. PhRMA claims that this level of disclosure will inhibit trial participants from signing up and also will promote second guessing of regulatory decisions -- both ideas being BAD in their view.
I guess they wouldn't be in favor of instant replay in baseball either? Oh wait, I got them confused with Bud Selig.
Posted by Bruce Lehr Feb 5th 2013.